Ostrom QT, Price M, Neff C, Cioffi G, Waite KA, Kruchko C, et al. CBTRUS Statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2015–2019. Neuro Oncol. 2022;24(Suppl 5):v1–95.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–96.

Article  CAS  PubMed  Google Scholar 

Stupp R, Taillibert S, Kanner A, Read W, Steinberg D, Lhermitte B, et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA. 2017;318(23):2306–16.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sener U, Ruff MW, Campian JL. Immunotherapy in glioblastoma: current approaches and future perspectives. Int J Mol Sci. 2022;23(13).

Wen PY, Weller M, Lee EQ, Alexander BM, Barnholtz-Sloan JS, Barthel FP, et al. Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro Oncol. 2020;22(8):1073–113.

Article  CAS  PubMed  PubMed Central  Google Scholar 

van den Bent MJ, Chang SM. Grade II and III Oligodendroglioma and Astrocytoma. Neurol Clin. 2018;36(3):467–84.

Article  PubMed  Google Scholar 

Dono A, Ballester LY, Primdahl D, Esquenazi Y, Bhatia A. IDH-mutant low-grade glioma: advances in molecular diagnosis, management, and future directions. Curr Oncol Rep. 2021;23(2):20.

Article  CAS  PubMed  Google Scholar 

Gritsch S, Batchelor TT, Gonzalez Castro LN. Diagnostic, therapeutic, and prognostic implications of the 2021 World Health Organization classification of tumors of the central nervous system. Cancer. 2022;128(1):47–58.

Article  PubMed  Google Scholar 

Gerstner ER, Batchelor TT. Imaging and response criteria in gliomas. Curr Opin Oncol. 2010;22(6):598–603.

Article  PubMed  Google Scholar 

Colman H. Adult gliomas. Continuum (Minneap Minn). 2020;26(6):1452–75.

PubMed  Google Scholar 

Zhou Q, Xue C, Ke X, Zhou J. Treatment response and prognosis evaluation in high-grade glioma: an imaging review based on MRI. J Magn Reson Imaging. 2022;56(2):325–40.

Article  PubMed  Google Scholar 

Zeng T, Xu Z, Yan J. The value of asphericity derived from T1-weighted MR in differentiating intraparenchymal ring-enhancing lesions-comparison of glioblastomas and brain abscesses. Neurol Sci. 2021;42(12):5171–5.

Article  PubMed  Google Scholar 

Choi C, Ganji SK, DeBerardinis RJ, Hatanpaa KJ, Rakheja D, Kovacs Z, et al. 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas. Nat Med. 2012;18(4):624–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Patel SH, Poisson LM, Brat DJ, Zhou Y, Cooper L, Snuderl M, et al. T2-FLAIR Mismatch, an imaging biomarker for IDH and 1p/19q status in lower-grade gliomas: a TCGA/TCIA project. Clin Cancer Res. 2017;23(20):6078–85.

Article  CAS  PubMed  Google Scholar 

Smits M. Imaging of oligodendroglioma. Br J Radiol. 2016;89(1060):20150857.

Article  PubMed  PubMed Central  Google Scholar 

Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. The 2021 WHO Classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021;23(8):1231–51.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Becker AP, Sells BE, Haque SJ, Chakravarti A. Tumor heterogeneity in glioblastomas: from light microscopy to molecular pathology. Cancers (Basel). 2021;13(4).

Olar A, Sulman EP. Molecular markers in low-grade glioma-toward tumor reclassification. Semin Radiat Oncol. 2015;25(3):155–63.

Article  PubMed  PubMed Central  Google Scholar 

Zhang P, Xia Q, Liu L, Li S, Dong L. Current Opinion on molecular characterization for GBM classification in guiding clinical diagnosis, prognosis, and therapy. Front Mol Biosci. 2020;7:562798.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, et al. The somatic genomic landscape of glioblastoma. Cell. 2013;155(2):462–77.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Riche M, Marijon P, Amelot A, Bielle F, Mokhtari K, Chambrun MP, et al. Severity, timeline, and management of complications after stereotactic brain biopsy. J Neurosurg. 2022;136(3):867–76.

Article  PubMed  Google Scholar 

Azad TD, Bettegowda C. Longitudinal monitoring of diffuse midline glioma using liquid biopsy. Neuro Oncol. 2022;24(8):1375–6.

Article  PubMed  PubMed Central  Google Scholar 

Lu VM, Power EA, Zhang L, Daniels DJ. Liquid biopsy for diffuse intrinsic pontine glioma: an update. J Neurosurg Pediatr. 2019;1–8.

• Miller AM, Shah RH, Pentsova EI, Pourmaleki M, Briggs S, Distefano N, et al. Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid. Nature. 2019;565(7741):654–8. This review discusses the technology behind CSF liquid biopsy in brain tumors, highlighting assay requirements that optimize efficency, cost and speed. This review also addresses the clinical utility of CSF liquid biopsies, including potential diagnostic value.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Friedman JS, Hertz CAJ, Karajannis MA, Miller AM. Tapping into the genome: the role of CSF ctDNA liquid biopsy in glioma. Neurooncol Adv. 2022;4(Suppl 2):ii33–40.

PubMed  PubMed Central  Google Scholar 

Miller AM, Szalontay L, Bouvier N, Hill K, Ahmad H, Rafailov J, et al. Next-generation sequencing of cerebrospinal fluid for clinical molecular diagnostics in pediatric, adolescent and young adult brain tumor patients. Neuro Oncol. 2022;24(10):1763–72.

Article  PubMed  PubMed Central  Google Scholar 

• Pasqualetti F, Rizzo M, Franceschi S, Lessi F, Paiar F, Buffa FM. New perspectives in liquid biopsy for glioma patients. Curr Opin Oncol. 2022;34(6):705–12. This commentary review collected data that demonstrates the potential of various CSF biomarkers to represent the high heterogeneity of brain tumors.

Article  CAS  PubMed  Google Scholar 

Eibl RH, Schneemann M. Liquid biopsy and primary brain tumors. Cancers (Basel). 2021;13(21).

Singh N, Miner A, Hennis L, Mittal S. Mechanisms of temozolomide resistance in glioblastoma - a comprehensive review. Cancer Drug Resist. 2021;4(1):17–43.

CAS  PubMed  PubMed Central  Google Scholar 

Slater JM, Shih HA. Pseudoprogression in low-grade glioma. Transl Cancer Res. 2019;8(Suppl 6):S580–4.

Article  PubMed  PubMed Central  Google Scholar 

Strauss SB, Meng A, Ebani EJ, Chiang GC. Imaging Glioblastoma posttreatment: progression, pseudoprogression, pseudoresponse, radiation necrosis. Radiol Clin North Am. 2019;57(6):1199–216.

Article  PubMed  Google Scholar 

Okada H, Weller M, Huang R, Finocchiaro G, Gilbert MR, Wick W, et al. Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncol. 2015;16(15):e534–42.

Article  PubMed  PubMed Central  Google Scholar 

Sidibe I, Tensaouti F, Roques M, Cohen-Jonathan-Moyal E, Laprie A. Pseudoprogression in glioblastoma: role of metabolic and functional MRI-systematic review. Biomedicines. 2022;10(2).

Nabavizadeh A, Bagley SJ, Doot RK, Ware JB, Young AJ, Ghodasara S, et al. Distinguishing progression from pseudoprogression in glioblastoma using (18)F-Fluciclovine PET. J Nucl Med. 2022.

Zach L, Guez D, Last D, Daniels D, Grober Y, Nissim O, et al. Delayed contrast extravasation MRI for depicting tumor and non-tumoral tissues in primary and metastatic brain tumors. PLoS One. 2012;7(12):e52008.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ellingson BM, Wen PY, Cloughesy TF. Modified criteria for radiographic response assessment in glioblastoma clinical trials. Neurotherapeutics. 2017;14(2):307–20.

Article  PubMed  PubMed Central  Google Scholar 

Ellingson BM, Sampson J, Achrol AS, Aghi MK, Bankiewicz K, Wang C, et al. Modified RANO, immunotherapy RANO, and standard RANO response to convection-enhanced delivery of IL4R-targeted immunotoxin MDNA55 in recurrent glioblastoma. Clin Cancer Res. 2021;27(14):3916–25.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ghersi-Egea JF, Strazielle N, Catala M, Silva-Vargas V, Doetsch F, Engelhardt B. Molecular anatomy and functions of the choroidal blood-cerebrospinal fluid barrier in health and disease. Acta Neuropathol. 2018;135(3):337–61.

Article  CAS  PubMed  Google Scholar 

•• Xiao F, Lv S, Zong Z, Wu L, Tang X, Kuang W, et al. Cerebrospinal fluid biomarkers for brain tumor detection: clinical roles and current progress. Am J Transl Res. 2020;12(4):1379–96. This review discusses the clinical roles of the most promising CSF biomarkers, including ctDNA, miRNA, and extracelluar vesicles.

CAS  PubMed  PubMed Central  Google Scholar 

Jahr S, Hentze H, Englisch S, Hardt D, Fackelmayer FO, Hesch RD, et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res. 2001;61(4):1659–65.

CAS  PubMed  Google Scholar 

Samuel N, Remke M, Rutka JT, Raught B, Malkin D. Proteomic analyses of CSF aimed at biomarker development for pediatric brain tumors. J Neurooncol. 2014;118(2):225–38.

Article  CAS